iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy

Journal: Science Translational Medicine

Published: 2020-11-04

DOI: 10.1126/scitranslmed.aaz5618

Affiliations: 4

Authors: 22

Go to article
Institutions Share
Fate Therapeutics, Inc., United States of America (USA) 0.59
University of Minnesota (UMN), United States of America (USA) 0.36
Sanford Consortium for Regenerative Medicine, United States of America (USA) 0.05